<DOC>
	<DOCNO>NCT01839734</DOCNO>
	<brief_summary>The use lubiprostone decrease level immune activation HIV-infected subject incomplete CD4+ T-cell recovery antiretroviral therapy ( ART ) . - Lubiprostone decrease level translocate gut microbial product HIV-infected subject incomplete CD4+ T-cell recovery ART . - The decrease level translocate gut microbial product associate decline level immune activation HIV-infected subject incomplete CD4+ T-cell recovery ART .</brief_summary>
	<brief_title>Pilot Study Lubiprostone Modulator Gut Microbial Translocation Systemic Immune Activation HIV-Infected Persons With Incomplete CD4+ T-cell Recovery Antiretroviral Therapy</brief_title>
	<detailed_description>Incomplete immune recovery HIV-infected individual associate impaired immune response antigen , opportunistic infection , cardiovascular disease malignancy , increase mortality . Several study point increased microbial translocation immune activation play causative role patient limit CD4 recovery antiretroviral therapy ( ART ) . The gut mucosa HIV-infected individual sustains rapid profound depletion gut mucosal CD4+ T-cells early day infection . These change lead defect mucosal immune epithelial barrier function allow translocation gut microbial product , plasma LPS ( endotoxin ) bacterial 16 DNA . Plasma endotoxin bacterial 16 DNA elevate HIV-infected individual level associate increased level immune activation . ART readily reverse deficit gut mucosal CD4+ T-cells . The epithelial barrier compose tight junction complex GI tract major defense must breach order microbial antigen enterotoxin express pathogenic bacteria traverse lumen intestine lamina propria GI tract . Given recent data demonstrate increased complication mortality HIV-infected individual despite suppressed viral replication ART , investigator propose adjunctive therapy aim reduce microbial translocation and/or inflammatory consequence could improve long-term prognosis HIV-infected individual . An intervention decrease level translocate gut microbial product use modulators act mucosal tight junction barrier strategy study HIV . LAMBCHOP randomize , open-label , control three-arm study test whether 4 week treatment lubiprostone , apical lumen ClC-2 chloride channel activator license treatment chronic idiopathic constipation irritable bowel syndrome constipation , reduces level translocate gut microbial product marker immune activation HIV-infected subject antiretroviral therapy incomplete CD4 recovery . Lubiprostone potent intestinal epithelial secretagogue show stimulate recovery mucosal barrier function via restoration tight junction protein complex ex vivo study ischemic porcine intestine . This study take advantage lubiprostone 's known effect vitro significantly decrease E. coli S. typhimurium translocation concentration-dependent manner vivo mouse study promote enhance protection translocate pathogenic bacteria shift intestinal microbiota order study role translocate gut microbial product drive immune activation HIV-infected subject . Blood sample stool specimen collect several time point study measure marker cellular activation , inflammation , gut translocation , coagulation . Safety assessment perform screening , entry , several post-entry visit . The primary objective study determine whether significant difference level immune activation gut microbiome 4 week study drug receive lubiprostone .</detailed_description>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>HIV1 infection , document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 antigen , plasma HIV1 RNA viral load . On tenofovir/emtricitabine/efavirenz single tablet combination therapy least 72 week prior study entry . No plan change antiretroviral regimen least next 3 month study entry . CD4+ cell count &lt; 350 cells/mm3 obtain within 120 day prior study entry laboratory Clinical Laboratory Improvement Amendments ( CLIA ) certification equivalent . All previous CD4+ cell count &lt; 350 cells/mm3 least 72 week prior study entry subject ART . Documentation HIV1 RNA limit detection ( e.g. , &lt; 50 copies/mL Roche Amplicor HIV1 Monitor assay , &lt; 75 copies/mL Versant HIV1 RNA assay branch DNA , &lt; 400 copies/mL standard Roche Amplicor assay , &lt; 40 copies/mL Abbott m2000sp/m2000rt realtime PCR test , &lt; 48 copies/mL COBAS AmpliPrep/TAQMAN HIV1 assay ) verify least two measurement prior study entry , one must least 48 week prior study entry one measurement obtain 121 day 48 week prior study entry . Screening HIV1 RNA limit detection obtain within 120 day prior study entry use FDA approve assay ( e.g. , &lt; 50 copies/mL Roche Amplicor HIV1 Monitor assay , &lt; 75 copies/mL Versant HIV1 RNA assay branch DNA , &lt; 40 copies/mL Abbott m2000sp/m2000rt realtime PCR test , &lt; 48 copies/mL COBAS AmpliPrep/TAQMAN HIV1 assay ) . Fasting laboratory value obtain within 45 day prior entry follow : Absolute neutrophil count ( ANC ) ≥ 1000/mm3 Hemoglobin ≥ 10.0 g/dL Platelet count ≥ 50,000/mm3 International normalize ratio ( INR ) Female subject reproductive potential ( defined girl reach menarche woman postmenopausal least 24 consecutive month ; i.e. , menses within precede 24 month undergone sterilization procedure [ hysterectomy , bilateral oophorectomy , bilateral tubal ligation , bilateral salpingectomy ] ) must negative serum urine βHCG pregnancy test sensitivity least 50 mIU/mL perform within 24 hour prior study entry . If participate sexual activity could lead pregnancy , female subject must agree use one form contraceptive list receive protocolspecified treatment 4 week stop treatment . If female subject reproductive potential ( girl reach menarche , woman postmenopausal least 24 consecutive month , woman undergo surgical sterilization , e.g. , hysterectomy , bilateral oophorectomy , bilateral tubal ligation salpingectomy ) , eligible without require use contraceptive . Self report acceptable documentation sterilization , contraceptive method , menopause . Men woman age ≥ 18 ≤ 65 year age . Ability willingness subject legally authorize representative provide inform consent . Active diarrhea ( 3 unformed stool per day ) within 28 day prior study entry ( except site investigator primary care provider attribute diarrhea antiretroviral azithromycin use ) . History active inflammatory bowel disease . History significant liver disease , define chronic liver disease ( include chronic alcoholic liver disease , hepatitis B C ) , plus either : ) ascites , b ) encephalopathy , c ) ChildPugh Score &gt; 7 . Receipt antimicrobial therapy within 30 day prior study entry . NOTE : Antimicrobial use prophylaxis opportunistic infection , e.g. , azithromycin trimethoprimsulfamethoxazole , allow . Active infection require use antibiotic within 30 day prior study entry . Known allergy/sensitivity hypersensitivity component study drug formulation . Serious illness require systemic treatment and/or hospitalization within 14 day prior entry . Use following medication 3 consecutive day within 60 day prior study entry : Immunosuppressives ( e.g. , azathioprine , corticosteroid [ physiologic replacement dos allow ] , cyclosporine , mycophenolate , NSAIDs ( nonsteroidal antiinflammatory drug ) , sirolimus , sulfasalazine , tacrolimus ) Immune modulators ( e.g. , cytokine [ e.g. , IL2 ] , granulocyte colony stimulate factor , growth hormone , tumor necrosis factor antagonist , thalidomide ) Antineoplastic agent Probiotics ( define product contain significant amount live microorganism ingest specific health benefit , e.g. , yogurt live active culture , Lactobacillus GG , Saccharomyces boulardii ) Anticoagulants ( e.g. , warfarin heparin ) Vaccinations within 1 week prior preentry study entry visit . NOTE : Subjects encourage get flu vaccine prior study preentry visit . Participation HIV immunotherapy/therapeutic vaccination trial within 6 month prior study entry . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>CD4+</keyword>
</DOC>